

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT	DISEASE Pancreas ductal adenocarcinoma	PHYSICIAN	ORDERING PHYSICIAN Yeh, Yi-Chen	SPECIMEN	SPECIMEN SITE Pancreas
	NAME Meng, Yuan Chiao		MEDICAL FACILITY Taipei Veterans General Hospital		SPECIMEN ID S111-71270M (PF22133)
	DATE OF BIRTH 22 November 1949		ADDITIONAL RECIPIENT None		SPECIMEN TYPE Slide Deck
	SEX Male		MEDICAL FACILITY ID 205872		DATE OF COLLECTION 06 September 2022
	MEDICAL RECORD # 43056399		PATHOLOGIST Not Provided		SPECIMEN RECEIVED 01 December 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

BRCA2 T2125fs*4
KRAS G12D
CDKN2A/B p16INK4a H83Y and p14ARF A97V
TP53 Q192*

1 Disease relevant genes with no reportable alterations: **BRCA1**

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Olaparib** (p. 8), **Rucaparib** (p. 9)
- Variants that may inform **nontargeted treatment approaches** (e.g., chemotherapy) in this tumor type: **BRCA2** T2125fs*4 (p. 4)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 11)
- Variants in select cancer susceptibility genes to consider for possible **follow-up germline testing** in the appropriate clinical context: **BRCA2** T2125fs*4 (p. 4)

BIOMARKER FINDINGS

Microsatellite status - MS-Stable

Tumor Mutational Burden - 0 Muts/Mb

GENOMIC FINDINGS

BRCA2 - T2125fs*4

10 Trials see p. 11

KRAS - G12D

3 Trials see p. 13

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

No therapies or clinical trials. See Biomarker Findings section

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
Olaparib 2A	Rucaparib 2A
	Niraparib
	Talazoparib
none	none

☐ NCCN category

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING IN SELECT CANCER SUSCEPTIBILITY GENES

Findings below have been previously reported as pathogenic germline in the ClinVar genomic database and were detected at an allele frequency of >10%. See appendix for details.

BRCA2 - T2125fs*4 p. [4](#)

This report does not indicate whether variants listed above are germline or somatic in this patient. In the appropriate clinical context, follow-up germline testing would be needed to determine whether a finding is germline or somatic.

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - p16INK4a H83Y and p14ARF **TP53** - Q192* p. [7](#)
A97V p. [6](#)

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

BIOMARKER FINDINGS

BIOMARKER

Microsatellite status

RESULT

MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors¹⁻³, including approved therapies nivolumab and pembrolizumab⁴. In a retrospective

analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, $p=0.001$)⁵.

FREQUENCY & PROGNOSIS

MSI is rare in pancreatic carcinoma, reported in less than 1% of samples ($n \geq 1,000$)⁶⁻¹⁰. The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022).

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive

amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor¹¹. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2¹¹⁻¹³. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers¹⁴⁻¹⁶. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins^{11,13,15-16}.

BIOMARKER

Tumor Mutational Burden

RESULT

0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1¹⁷⁻¹⁹, anti-PD-1 therapies¹⁷⁻²⁰, and combination nivolumab and ipilimumab²¹⁻²⁶. In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors^{17-20,27-31}. In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥ 10 Muts/Mb (as measured by this assay) compared with those with TMB < 10 Muts/Mb in a large cohort that included multiple tumor types²⁷; similar findings were observed in the KEYNOTE 028 and 012 trials²⁰. At the same TMB cutpoint, retrospective analysis of

patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores < 10 muts/Mb ($HR=0.68$)³¹. For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples³². However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and < 16 Muts/Mb³⁰. Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as $\geq 16-20$ Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy³³ or those with lower TMB treated with PD-1 or PD-L1-targeting agents¹⁸.

FREQUENCY & PROGNOSIS

Pancreatic carcinomas, including ductal and acinar subtypes, have been reported to harbor a median TMB of 2-3 mutations per megabase (muts/Mb), and 0-2% of cases have high TMB (> 20 muts/

Mb)³⁴; TMB has not been assessed in pancreatic mucinous neoplasms (PubMed, Oct 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as > 50 mutations; survival 69-314 months) compared to those with lower TMB (average of 5.7 mutations; 10-42 months)³⁵.

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma³⁶⁻³⁷ and cigarette smoke in lung cancer³⁸⁻³⁹, treatment with temozolomide-based chemotherapy in glioma⁴⁰⁻⁴¹, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes⁴²⁻⁴⁶, and microsatellite instability (MSI)^{42,45-46}. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types^{18-19,27}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

GENOMIC FINDINGS

GENE

BRCA2

ALTERATION

T2125fs*4

TRANSCRIPT ID

NM_000059.3

CODING SEQUENCE EFFECT

6373_6374insA

VARIANT CHROMOSOMAL POSITION

chr13:32914859

VARIANT ALLELE FREQUENCY (% VAF)

17.6%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors⁴⁷⁻⁶⁴ or ATR inhibitors⁶⁵⁻⁶⁷. Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations^{48,53,56,63-64} and for patients with platinum-resistant or -refractory disease^{47,52,59,62}. A randomized Phase 2 trial evaluating cisplatin and gemcitabine with or without veliparib in 50 patients with advanced pancreatic ductal adenocarcinomas (PDAC) harboring germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutations reported that the addition of the PARP inhibitor veliparib to chemotherapy did not significantly improve median PFS (10.1 vs. 9.7 months) or median OS (15.5 vs. 16.4 months) relative to chemotherapy alone⁶⁸. The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP-inhibitor, olaparib. In a Phase 2 study for patients with PARP-resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA-mutated cohort, no significant difference in clinical

benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments⁶⁹. In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2-mutated solid tumors, 2 patients with BRCA1-mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression⁷⁰. In a case study, a patient with therapy-induced neuroendocrine prostate cancer and an inactivating BRCA2 rearrangement experienced a CR ongoing for 20 months to the ATR inhibitor berzosertib⁶⁷. Preclinical studies of BRCA1/2 inactivation in T-cell acute lymphoblastic leukemia (T-ALL)⁷¹, ovarian carcinoma⁷², and triple-negative breast cancer (TNBC)⁷³ showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA2-deficient cells to ATR inhibitors. The Phase 1/2 PETRA study of PARP1 inhibitor AZD5305 observed a 25% (10/40) ORR (10 PR), for patients with BRCA1/2, PALB2, or RAD51C-mutated breast, ovarian, pancreatic, or prostate cancer, including 5 patients with prior PARP inhibitor treatment⁷⁴.

— Nontargeted Approaches —

Inactivation of BRCA2 may also predict sensitivity to DNA-damaging drugs such as trabectedin, lurbinectedin, and the platinum chemotherapies cisplatin and carboplatin⁷⁵⁻⁸⁵. Patients with pancreatic cancer and BRCA1/2 or PALB2 mutations may benefit from FOLFIRINOX, or the combination of cisplatin and gemcitabine (NCCN Pancreatic Adenocarcinoma Guidelines, v1.2022)^{68,86-89}.

FREQUENCY & PROGNOSIS

BRCA2 mutations have been observed in 1-2% of pancreatic carcinomas⁹⁰⁻⁹¹. Germline mutations in BRCA1 and BRCA2 have been linked to an

increased risk of pancreatic adenocarcinoma⁹²⁻⁹⁴, and BRCA1/2 loss of heterozygosity (LOH) has been reported in 3 of 4 pancreatic ductal adenocarcinomas associated with the BRCA2 germline mutation 6174delT⁹⁵.

FINDING SUMMARY

The BRCA2 tumor suppressor gene encodes a protein that regulates the response to DNA damage⁹⁶. Inactivating mutations in BRCA2 can lead to the inability to repair DNA damage and loss of cell cycle checkpoints, which can lead to tumorigenesis⁹⁷. Alterations such as seen here may disrupt BRCA2 function or expression^{96,98-113}.

POTENTIAL GERMLINE IMPLICATIONS

One or more of the BRCA2 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary breast and ovarian cancer syndrome (ClinVar, Sep 2022)¹¹⁴. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer¹¹⁵⁻¹¹⁶, and the lifetime risk of breast and ovarian cancer in BRCA2 mutation carriers has been estimated to be as high as >80% and 23%, respectively¹¹⁷. Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60%¹¹⁸. The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10-fold higher prevalence in the Ashkenazi Jewish population^{117,119-124}. In the appropriate clinical context, germline testing of BRCA2 is recommended.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

GENOMIC FINDINGS

GENE

KRAS

ALTERATION

G12D

TRANSCRIPT ID

NM_004985.3

CODING SEQUENCE EFFECT

35G>A

VARIANT CHROMOSOMAL POSITION

chr12:25398284

VARIANT ALLELE FREQUENCY (% VAF)

15.6%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib¹²⁵⁻¹³⁰. For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS-mutated, PD-L1 positive disease¹³¹. Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS-mutated pancreatic tumors¹³²⁻¹³³. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine

experienced a PR¹³². A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months¹³⁴. A Phase 1b study of second-line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10)¹³⁵; an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin¹³⁶. Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors¹³⁷ or PI3K-AKT pathway inhibitors¹³⁸⁻¹³⁹, reported no PRs and frequent adverse events for patients with KRAS-mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status¹⁴⁰⁻¹⁴³, despite promising results in earlier trials of MEK inhibitor monotherapies¹⁴⁴⁻¹⁴⁹. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NSCLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma¹⁵⁰. Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS-mutated low-grade serous ovarian cancer and 12% (2/17) for patients with KRAS-mutated non-small cell lung cancer (NSCLC) in a Phase 1 study¹⁵¹⁻¹⁵². Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors¹⁵³⁻¹⁵⁴. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with

NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations¹⁵⁵. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer¹⁵⁶. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors¹⁵⁷⁻¹⁵⁸. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations¹⁵⁹⁻¹⁶⁰.

FREQUENCY & PROGNOSIS

KRAS mutations have been observed in 91-95% of pancreatic ductal adenocarcinoma cases^{90,161}, with the majority of mutations found at codon 12¹⁶²⁻¹⁶⁵. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma¹⁶³.

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation^{126,166}. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic^{126,167-189}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

GENOMIC FINDINGS

GENE

CDKN2A/B

ALTERATION

p16INK4a H83Y and p14ARF A97V

TRANSCRIPT ID

NM_000077.4

CODING SEQUENCE EFFECT

247C>T

VARIANT CHROMOSOMAL POSITION

chr9:21971111

VARIANT ALLELE FREQUENCY (% VAF)

16.8%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib¹⁹⁰⁻¹⁹³. Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib¹⁹⁴ and palbociclib treatment¹⁹⁵⁻¹⁹⁶. However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents¹⁹⁷⁻²⁰³; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors²⁰⁴⁻²⁰⁵, the clinical relevance of p14ARF as a predictive biomarker is not clear.

FREQUENCY & PROGNOSIS

CDKN2A/B loss has been reported in 36% of pancreatic ductal carcinomas⁹⁰. CDKN2A loss has been reported in 25-100% of pancreatic ductal adenocarcinomas analyzed, with a portion of those due to gene deletion^{163,206-208}. A study of multiple pancreatic cancer subtypes reported no CDKN2A mutations (0/6 samples) and loss of heterozygosity in only one of four samples of pancreatic acinar carcinomas, compared to mutation or loss of heterozygosity in 38% and 67% of pancreatic ductal carcinomas, respectively²⁰⁹. Promoter methylation affecting p16INK4a and p14ARF has been reported in 43% (16/37) and 20.6% (7/34), respectively, of pancreatic fluid specimens of patients with pancreatic carcinoma²¹⁰. The loss or decrease of p16INK4a expression levels in pancreatic ductal adenocarcinoma has been reported in 32-80% of samples analyzed and one study reported concurrent loss of p16INK4a and p14ARF protein expression in 68% (19/28) of cases^{206,211-212}. p16INK4a expression has been associated with improved overall survival in pancreatic adenocarcinoma patients in univariate and multivariate analysis²¹³. Furthermore, CDKN2A alterations (deletion or mutation) in the presence of concomitant KRAS mutation may correlate with shorter survival in patients with pancreatic ductal adenocarcinoma²¹¹.

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b²¹⁴⁻²¹⁵. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby

maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control²¹⁶⁻²¹⁷. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition²¹⁸⁻²¹⁹. One or more alterations observed here are predicted to result in p16INK4a loss of function²²⁰⁻²⁴¹. One or more alterations seen here have been observed in the context of cancer but have not been characterized and their effect on p14ARF function is unclear.

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer²⁴². Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma²⁴³⁻²⁴⁴. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases²⁴⁵⁻²⁴⁷. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors²⁴⁸⁻²⁵⁰. In the appropriate clinical context, germline testing of CDKN2A is recommended.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

GENOMIC FINDINGS

GENE

TP53

ALTERATION

Q192*

TRANSCRIPT ID

NM_000546.4

CODING SEQUENCE EFFECT

574C>T

VARIANT CHROMOSOMAL POSITION

chr17:7578275

VARIANT ALLELE FREQUENCY (% VAF)

17.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib²⁵¹⁻²⁵⁴ or p53 gene therapy such as SGT53²⁵⁵⁻²⁵⁹. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype²⁶⁰. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer²⁶¹. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer²⁶². The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone²⁶³. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel²⁶⁴. A Phase 1 trial of

neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations²⁶⁵. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring²⁶⁶. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage²⁵⁹. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR²⁶⁷. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)²⁶⁸.

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 33-75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases^{161,269-271}. TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis²⁷²⁻²⁷³. Additionally, aberrant expression of p53 has been found in 54-81% of pancreatic ductal adenocarcinoma cases^{211,270,274-275}. Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis^{211,276-277}.

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in

aggressive advanced cancers²⁷⁸. Alterations such as seen here may disrupt TP53 function or expression²⁷⁹⁻²⁸³.

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2022)¹¹⁴. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers²⁸⁴⁻²⁸⁶, including sarcomas²⁸⁷⁻²⁸⁸. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000²⁸⁹ to 1:20,000²⁸⁸. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30²⁹⁰. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion²⁹¹⁻²⁹⁶. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy²⁹¹⁻²⁹². Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease²⁹⁷. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{295,298-299}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

THERAPIES WITH CLINICAL BENEFIT

IN PATIENT'S TUMOR TYPE

Olaparib

Assay findings association
BRCA2
T2125fs*4

AREAS OF THERAPEUTIC USE

The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA-mutated pancreatic adenocarcinoma or HER2-negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of extensive clinical evidence in ovarian cancer⁵⁷⁻⁶¹ as well as strong clinical evidence in multiple other cancer types^{47-49,57,60,64,300}, loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib.

SUPPORTING DATA

The Phase 3 randomized, placebo-controlled POLO trial

investigating maintenance olaparib for patients with platinum-sensitive, germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma reported a significantly longer median PFS compared with placebo (7.4 vs. 3.8 months, HR=0.53)⁶⁴. At 3-year follow-up, an OS of 34% was reported for patients treated with olaparib compared with 18% for patients receiving placebo; however, olaparib maintenance therapy did not impact median OS (19.0 vs. 19.2 months, HR=0.83) relative to placebo³⁰¹. A Phase 2 trial of olaparib monotherapy for patients with germline BRCA1/2-mutated recurrent pancreatic cancer reported a response rate of 22%⁴⁷. Parallel Phase 2 trials reported 2 PRs for patients with platinum-sensitive, DNA damage repair (DDR) deficient, germline BRCA mutation-negative pancreatic ductal adenocarcinoma; no responses were observed in platinum-refractory cases³⁰². In a Phase 2 study of olaparib plus pembrolizumab for advanced solid tumors, patients with BRCA1 or BRCA2 mutations achieved an ORR of 29% (6/21), whereas patients with mutations in other homologous recombination repair genes achieved an ORR of 6.3% (2/32)³⁰³.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

THERAPIES WITH CLINICAL BENEFIT
IN OTHER TUMOR TYPE

Niraparib

Assay findings association
BRCA2
 T2125fs*4

AREAS OF THERAPEUTIC USE

The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)-positive status. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in ovarian and breast cancers^{51-52,304}, loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib.

SUPPORTING DATA

In a Phase 1b/2 study, 6-month PFS for patients with advanced pancreatic cancer treated with niraparib plus ipilimumab in the maintenance setting was 60% whereas those treated with niraparib plus nivolumab was 21%³⁰⁵. Niraparib has been primarily evaluated in the context of

ovarian cancer. In a Phase 3 study of patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination-deficient tumors (12.9 vs. 3.8 months)⁵¹. In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration-resistant prostate cancer and 100% (2/2) of patients with non-small cell lung cancer achieved SD⁵². A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum-sensitive, high-grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)³⁰⁶.

Rucaparib

Assay findings association
BRCA2
 T2125fs*4

AREAS OF THERAPEUTIC USE

The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical evidence in ovarian cancer^{53-54,261}, as well as clinical data in other cancer types^{54,307-308}, loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib.

SUPPORTING DATA

In the RUCAPANC Phase 2 study, rucaparib elicited an ORR of 16% and a DCR of 32% for BRCA1/2-mutated advanced or metastatic pancreatic cancer, with 2 CRs (1 confirmed, 1 unconfirmed) and 2 PRs out of 19 treated patients³⁰⁹. As maintenance therapy for BRCA1/2- or PALB2-mutated platinum-sensitive pancreatic cancer, rucaparib enabled a 6-month PFS rate of 60%, median PFS and OS of 13.1 and 23.5 months, and ORR of 41% (3/36 CRs, 2 ongoing for >1 year) in a Phase 2 study; 4 patients remained progression-free during >2 years of follow up³¹⁰⁻³¹¹. In this trial, ORRs for patients with germline or somatic BRCA2 alterations were 41% (11/27) and 50% (1/2), respectively, and 50% (3/6) for those with germline PALB2 alterations; however, no objective responses were observed for any of 7 patients with germline BRCA1 alterations³¹⁰.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Talazoparib

Assay findings association
BRCA2
T2125fs*4

AREAS OF THERAPEUTIC USE

The PARP inhibitor talazoparib is FDA approved to treat HER2-negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical data in breast cancer³¹²⁻³¹⁴ and additional clinical evidence in ovarian, pancreatic, and prostate cancer³¹⁵⁻³¹⁸, loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib.

SUPPORTING DATA

A Phase 1 study of talazoparib reported PRs for 20% (2/10) of patients with pancreatic cancer, 1 with a BRCA2 mutation and 1 with a PALB2 mutation³¹⁶. Talazoparib has been studied primarily in the context of BRCA-mutated,

HER2-negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study³¹³⁻³¹⁴. In a Phase 2 study of talazoparib for BRCA1/2-wildtype patients with homologous recombination pathway alterations, the best outcome in non-breast tumors was SD ≥ 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration³¹⁹. Clinical activity of single-agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA-mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2-mutated pancreatic and bladder cancers; ATM-mutated cholangiocarcinoma; and small cell lung cancer^{315-317,320}.

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually

updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that

may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit <https://www.foundationmedicine.com/genomic-testing#support-services>.

GENE
BRCA2
ALTERATION
 T2125fs*4

RATIONALE
 BRCA2 loss or inactivating alterations may predict inhibitors. sensitivity to PARP inhibitors or to ATR

NCT04300114
PHASE 3

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

TARGETS
 PARP

LOCATIONS: Hangzhou (China), Shanghai (China), Nanjing (China), Hefei (China), Guangzhou (China), Wuhan (China), Zhengzhou (China), Jinan (China), Chongqing (China), Tianjin (China)

NCT04644068
PHASE 1/2

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

TARGETS
 ERBB2, TROP2, PARP

LOCATIONS: Shanghai (China), Guangzhou (China), Seoul (Korea, Republic of), Chongqing (China), Chuo-ku (Japan), Koto-ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Bydgoszcz (Poland)

NCT04228601
PHASE 1/2

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

TARGETS
 PARP

LOCATIONS: Hangzhou (China), Shanghai (China)

NCT03239015
PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
 EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04425876
PHASE 1

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

TARGETS
 PARP

LOCATIONS: Shanghai (China)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

CLINICAL TRIALS
NCT04123366
PHASE 2

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

TARGETS
PARP, PD-1

LOCATIONS: Fukuoka (Japan), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)

NCT03742895
PHASE 2

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

TARGETS
PARP

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Beer-Sheva (Israel), Istanbul (Turkey)

NCT02264678
PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)

NCT05035745
PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561
PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

CLINICAL TRIALS
GENE
KRAS
ALTERATION
G12D
RATIONALE

Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS-mutant pancreatic cancer. Emerging data suggest patients with KRAS-mutant pancreatic cancer may be sensitive to

combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors.

NCT03825289
PHASE 1

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

TARGETS
MEK
LOCATIONS: Utah

NCT04892017
PHASE 1/2

A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.

TARGETS
ULK1, ULK2, MEK
LOCATIONS: Massachusetts, Texas, Pennsylvania

NCT04132505
PHASE 1

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

TARGETS
MEK
LOCATIONS: Texas

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

AKT1
 I75M

ATM
 I2223V

DIS3
 A656V

ERBB3
 R967K

IDH2
 M397V

MSH6
 K1358fs*2

PTCH1
 D1222N

SMAD4
 S271N

TBX3
 A562V

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

APPENDIX
Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B or WTX)	
APC	AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX
AURKA	AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAS	GNAS	GRM3	GSK3B	H3-3A (H3F3A)
HDAC1	HGF	HNFA1	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11 (MRE11A)	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	NTRK3
P2RY8	PALB2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCCD1 (PD-1)	PDCCD1LG2 (PD-L2)
PDGFRA	PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1
PMS2	POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI
PRKN (PARK2)	PTCH1	PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51
RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10
REL	RET	RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO
SNCAIP	SOC1	SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3
STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)	TET2	TET2	TGFB2
TIPARP	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3	U2AF1	VEGFA
VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated


ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1514793-01

APPENDIX
About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a., Ciplstraat 3, 2440 Geel, Belgium. 

ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:
www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes

detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical

methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fraction-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

APPENDIX

About FoundationOne®CDx

- analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.
- TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
 - Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16 will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
 - The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and

- extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
- Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
 - Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
 - Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of *HER2* overexpression as 20% in breast cancer. Based on the F1CDx *HER2* CDx concordance study, approximately 10% of *HER2* amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal

hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1514793-01

APPENDIX

About FoundationOne®CDx

tumor sequencing is germline or somatic.
 Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D (MLL2)*, *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking

into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.4.0

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of the data. The median exon coverage for this sample is 845x. The suitability of use.

ORDERED TEST # **ORD-1514793-01**
APPENDIX
References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) PMID: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) PMID: 26140250
3. Lal N, et al. Oncoimmunology (2015) PMID: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) PMID: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Hu ZI, et al. Clin. Cancer Res. (2018) PMID: 29367431
7. Campbell BB, et al. Cell (2017) PMID: 29056344
8. Pihlak R, et al. Cancers (Basel) (2018) PMID: 29329208
9. Salem ME, et al. Mol. Cancer Res. (2018) PMID: 29523759
10. Laghi L, et al. PLoS ONE (2012) PMID: 23029359
11. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) PMID: 26337942
12. You JF, et al. Br. J. Cancer (2010) PMID: 21081928
13. Bairwa NK, et al. Methods Mol. Biol. (2014) PMID: 24623249
14. Boland CR, et al. Cancer Res. (1998) PMID: 9823339
15. Pawlik TM, et al. Dis. Markers (2004) PMID: 15528785
16. Boland CR, et al. Gastroenterology (2010) PMID: 20420947
17. Samstein RM, et al. Nat. Genet. (2019) PMID: 30643254
18. Goodman AM, et al. Mol. Cancer Ther. (2017) PMID: 28835386
19. Goodman AM, et al. Cancer Immunol Res (2019) PMID: 31405947
20. Cristescu R, et al. Science (2018) PMID: 30309915
21. Ready N, et al. J. Clin. Oncol. (2019) PMID: 30785829
22. Hellmann MD, et al. N. Engl. J. Med. (2018) PMID: 29658845
23. Hellmann MD, et al. Cancer Cell (2018) PMID: 29657128
24. Hellmann MD, et al. Cancer Cell (2018) PMID: 29731394
25. Rozeman EA, et al. Nat Med (2021) PMID: 33558721
26. Sharma P, et al. Cancer Cell (2020) PMID: 32916128
27. Marabelle A, et al. Lancet Oncol. (2020) PMID: 32919526
28. Ott PA, et al. J. Clin. Oncol. (2019) PMID: 30557521
29. Cristescu R, et al. J Immunother Cancer (2022) PMID: 35101941
30. Friedman CF, et al. Cancer Discov (2022) PMID: 34876409
31. Sturgill EG, et al. Oncologist (2022) PMID: 35274716
32. Schenker et al., 2022; AACR Abstract 7845
33. Legrand et al., 2018; ASCO Abstract 12000
34. Chalmers ZR, et al. Genome Med (2017) PMID: 28420421
35. Hu et al., 2017; ASCO Abstract e15791
36. Pfeifer GP, et al. Mutat. Res. (2005) PMID: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) PMID: 23875803
38. Pfeifer GP, et al. Oncogene (2002) PMID: 12379884
39. Rizvi NA, et al. Science (2015) PMID: 25765070
40. Johnson BE, et al. Science (2014) PMID: 24336570
41. Choi S, et al. Neuro-oncology (2018) PMID: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) PMID: 23636398
43. Briggs S, et al. J. Pathol. (2013) PMID: 23447401
44. Heitzner E, et al. Curr. Opin. Genet. Dev. (2014) PMID: 24583393
45. Nature (2012) PMID: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) PMID: 25568919
47. Kaufman B, et al. J. Clin. Oncol. (2015) PMID: 25366685
48. Mateo J, et al. N. Engl. J. Med. (2015) PMID: 26510020
49. Tutt A, et al. Lancet (2010) PMID: 20609467
50. Robson M, et al. N. Engl. J. Med. (2017) PMID: 28578601
51. Mirza MR, et al. N. Engl. J. Med. (2016) PMID: 27717299
52. Sandhu SK, et al. Lancet Oncol. (2013) PMID: 23810788
53. Swisher EM, et al. Lancet Oncol. (2017) PMID: 27908594
54. Drew Y, et al. Br. J. Cancer (2016) PMID: 27002934
55. Pujade-Lauraine E, et al. Lancet Oncol. (2017) PMID: 28754483
56. Ledermann JA, et al. Lancet Oncol. (2016) PMID: 27617661
57. Fong PC, et al. N. Engl. J. Med. (2009) PMID: 19553641
58. Audeh MW, et al. Lancet (2010) PMID: 20609468
59. Fong PC, et al. J. Clin. Oncol. (2010) PMID: 20406929
60. Gelmon KA, et al. Lancet Oncol. (2011) PMID: 21862407
61. Kaye SB, et al. J. Clin. Oncol. (2012) PMID: 22203755
62. Domchek SM, et al. Gynecol. Oncol. (2016) PMID: 26723501
63. Moore K, et al. N. Engl. J. Med. (2018) PMID: 30345884
64. Golan T, et al. N. Engl. J. Med. (2019) PMID: 31157963
65. Yap TA, et al. Cancer Discov (2021) PMID: 32988960
66. Thomas A, et al. J. Clin. Oncol. (2018) PMID: 29252124
67. Saito YD, et al. Cancer Treat Res Commun (2018) PMID: 31299005
68. O'Reilly EM, et al. J. Clin. Oncol. (2020) PMID: 31976786
69. Westin et al., 2021; ASCO Abstract 5505
70. Do K, et al. J. Clin. Oncol. (2015) PMID: 25964244
71. Pouliot GP, et al. PLoS ONE (2019) PMID: 31721781
72. Kim H, et al. Clin. Cancer Res. (2017) PMID: 27993965
73. Jin J, et al. Neoplasia (2018) PMID: 29605721
74. Yap et al., 2022; AACR Abstract CT007
75. Isakoff SJ, et al. J. Clin. Oncol. (2015) PMID: 25847936
76. Dann RB, et al. Gynecol. Oncol. (2012) PMID: 22406760
77. Evers B, et al. Clin. Cancer Res. (2008) PMID: 18559613
78. Soares DG, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) PMID: 17656556
79. Miolo G, et al. Cancer Biol. Ther. (2016) PMID: 27561088
80. Ghoadni A, et al. Breast (2017) PMID: 28467918
81. Case Rep Oncol () PMID: 28626402
82. Monk BJ, et al. Gynecol. Oncol. (2020) PMID: 31924332
83. Harnicek D, et al. Int. J. Cancer (2016) PMID: 26933761
84. Cruz C, et al. J. Clin. Oncol. (2018) PMID: 30240327
85. Poveda A, et al. Ann. Oncol. (2017) PMID: 28368437
86. Conroy T, et al. N Engl J Med (2011) PMID: 21561347
87. Fogelman D, et al. Cancer Chemother Pharmacol (2015) PMID: 26126726
88. Wattenberg MM, et al. Br J Cancer (2020) PMID: 31787751
89. Golan T, et al. Br J Cancer (2014) PMID: 25072261
90. Witkiewicz AK, et al. Nat Commun (2015) PMID: 25855536
91. Bailey P, et al. Nature (2016) PMID: 26909576
92. Hahn SA, et al. J. Natl. Cancer Inst. (2003) PMID: 12569143
93. Lowery MA, et al. Oncologist (2011) PMID: 21934105
94. Mocci E, et al. Cancer Epidemiol. Biomarkers Prev. (2013) PMID: 23456555
95. Lucas AL, et al. Clin. Cancer Res. (2013) PMID: 23658460
96. Yang H, et al. Science (2002) PMID: 12228710
97. Nat. Struct. Mol. Biol. (2011) PMID: 21731065
98. Biswas K, et al. Blood (2011) PMID: 21719596
99. Biswas K, et al. Hum. Mol. Genet. (2012) PMID: 22678057
100. Claes K, et al. Br. J. Cancer (2004) PMID: 15026808
101. Cote S, et al. Breast Cancer Res. Treat. (2012) PMID: 21947752
102. Fackenthal JD, et al. Am. J. Hum. Genet. (2002) PMID: 12145750
103. Farrugia DJ, et al. Cancer Res. (2008) PMID: 18451181
104. Gómez García EB, et al. Breast Cancer Res. (2009) PMID: 19200354
105. Guidugli L, et al. Cancer Res. (2013) PMID: 23108138
106. Kluska A, et al. BMC Med Genomics (2015) PMID: 25948282
107. Kuznetsov SG, et al. Nat. Med. (2008) PMID: 18607349
108. Roy R, et al. Nat. Rev. Cancer (2011) PMID: 22193408
109. Siald N, et al. PLoS Genet. (2011) PMID: 22194698
110. Thomassen M, et al. Genet. Test. (2006) PMID: 16792514
111. Xia B, et al. Mol. Cell (2006) PMID: 16793542
112. Guidugli L, et al. Am. J. Hum. Genet. (2018) PMID: 29394989
113. Fraile-Bethencourt E, et al. PLoS Genet. (2017) PMID: 28339459
114. Landrum MJ, et al. Nucleic Acids Res. (2018) PMID: 29165669
115. Miki Y, et al. Science (1994) PMID: 7545954
116. Wooster R, et al. Nature () PMID: 8524414
117. King MC, et al. Science (2003) PMID: 14576434
118. MedGenMed (2005) PMID: 16369438
119. Ford D, et al. Lancet (1994) PMID: 7907678
120. Whittemore AS, et al. Am. J. Hum. Genet. (1997) PMID: 9042908
121. Claus EB, et al. Cancer (1996) PMID: 8635102
122. Struwing JP, et al. N. Engl. J. Med. (1997) PMID: 9145676
123. Oddoux C, et al. Nat. Genet. (1996) PMID: 8841192
124. Hall MJ, et al. Cancer (2009) PMID: 19241424
125. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) PMID: 6320174
126. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) PMID: 21993244
127. Yamaguchi T, et al. Int. J. Oncol. (2011) PMID: 21523318
128. Watanabe M, et al. Cancer Sci. (2013) PMID: 23438367
129. Gilmartin AG, et al. Clin. Cancer Res. (2011) PMID: 21245089
130. Yeh JJ, et al. Mol. Cancer Ther. (2009) PMID: 19372556
131. Zhu X, et al. Lancet Oncol (2022) PMID: 35240087
132. Kinsey CG, et al. Nat. Med. (2019) PMID: 30833748
133. Bryant KL, et al. Nat. Med. (2019) PMID: 30833752
134. Mahalingam D, et al. Cancers (Basel) (2018) PMID: 29799479
135. Mahalingam D, et al. Clin. Cancer Res. (2019) PMID: 31694832
136. Noonan AM, et al. Mol. Ther. (2016) PMID: 27039845
137. Ko AH, et al. Clin. Cancer Res. (2016) PMID: 26251290
138. Chung V, et al. JAMA Oncol (2017) PMID: 27978579
139. Bedard PL, et al. Clin. Cancer Res. (2015) PMID: 25500057
140. Van Laethem JL, et al. Target Oncol (2017) PMID: 27975152
141. Infante JR, et al. Eur. J. Cancer (2013) PMID: 23583440
142. Infante JR, et al. Eur. J. Cancer (2014) PMID: 24915778
143. Van Cutsem E, et al. Int. J. Cancer (2018) PMID: 29756206
144. Bodoky G, et al. Invest New Drugs (2012) PMID: 21594619
145. Rinehart J, et al. J. Clin. Oncol. (2004) PMID: 15483017
146. Lorusso PM, et al. J. Clin. Oncol. (2005) PMID: 16009947
147. Infante JR, et al. Lancet Oncol. (2012) PMID: 22805291
148. Weekes CD, et al. Clin. Cancer Res. (2013) PMID: 23434733
149. Garrido-Laguna I, et al. Oncoscience (2015) PMID:

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1514793-01

APPENDIX

References

- 25897431
150. Guo C, et al. Lancet Oncol (2020) PMID: 33128873
151. Krebs et al., 2021; AACR Abstract CT019
152. Shinde et al., 2020; AACR Abstract CT143
153. Lu H, et al. Mol Cancer Ther (2019) PMID: 31068384
154. Mainardi S, et al. Nat Med (2018) PMID: 29808006
155. Koczywas et al., 2021; AACR Abstract LB001
156. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
157. Hillig RC, et al. Proc Natl Acad Sci U S A (2019) PMID: 30683722
158. Hofmann MH, et al. Cancer Discov (2021) PMID: 32816843
159. Hofmann et al., 2021; AACR Abstract CT210
160. Gort et al., 2020; ASCO Abstract TPS3651
161. Biankin AV, et al. Nature (2012) PMID: 23103869
162. Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) PMID: 17520196
163. Rachakonda PS, et al. PLoS ONE (2013) PMID: 23565280
164. Hruban RH, et al. Am. J. Pathol. (1993) PMID: 8342602
165. Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) PMID: 16549325
166. Kahn S, et al. Anticancer Res. () PMID: 3310850
167. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) PMID: 17150185
168. Bollag G, et al. J. Biol. Chem. (1996) PMID: 8955068
169. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) PMID: 20194776
170. Sci. STKE (2004) PMID: 15367757
171. Edkins S, et al. Cancer Biol. Ther. (2006) PMID: 16969076
172. Feig LA, et al. Mol. Cell. Biol. (1988) PMID: 3043178
173. Gremer L, et al. Hum. Mutat. (2011) PMID: 20949621
174. Janakiraman M, et al. Cancer Res. (2010) PMID: 20570890
175. Kim E, et al. Cancer Discov (2016) PMID: 27147599
176. Lukman S, et al. PLoS Comput. Biol. (2010) PMID: 20835576
177. Naguib A, et al. J Mol Signal (2011) PMID: 21371307
178. Prior IA, et al. Cancer Res. (2012) PMID: 22589270
179. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) PMID: 1565661
180. Scheffzek K, et al. Science (1997) PMID: 9219684
181. Scholl C, et al. Cell (2009) PMID: 19490892
182. Smith G, et al. Br. J. Cancer (2010) PMID: 20147967
183. Tyner JW, et al. Blood (2009) PMID: 19075190
184. Valencia A, et al. Biochemistry (1991) PMID: 2029511
185. White Y, et al. Nat Commun (2016) PMID: 26854029
186. Wiest JS, et al. Oncogene (1994) PMID: 8058307
187. Angeles AKJ, et al. Oncol Lett (2019) PMID: 31289513
188. Tong JH, et al. Cancer Biol. Ther. (2014) PMID: 24642870
189. Loree JM, et al. Clin Cancer Res (2021) PMID: 34117033
190. Konecny GE, et al. Clin. Cancer Res. (2011) PMID: 21278246
191. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) PMID: 21871868
192. Cen L, et al. Neuro-oncology (2012) PMID: 22711607
193. Logan JE, et al. Anticancer Res. (2013) PMID: 23898052
194. Fennell DA, et al. Lancet Oncol (2022) PMID: 35157829
195. Elvin JA, et al. Oncologist (2017) PMID: 28283584
196. Gao J, et al. Curr Oncol (2015) PMID: 26715889
197. Gopalan et al., 2014; ASCO Abstract 8077
198. Peguero et al., 2016; ASCO Abstract 2528
199. Konecny et al., 2016; ASCO Abstract 5557
200. DeMichele A, et al. Clin. Cancer Res. (2015) PMID: 25501126
201. Finn RS, et al. Lancet Oncol. (2015) PMID: 25524798
202. Infante JR, et al. Clin. Cancer Res. (2016) PMID: 27542767
203. Johnson DB, et al. Oncologist (2014) PMID: 24797823
204. Van Maerken T, et al. Mol. Cancer Ther. (2011) PMID: 21460101
205. Gamble LD, et al. Oncogene (2012) PMID: 21725357
206. Tsiambas E, et al. J BUON () PMID: 17600882
207. Bergmann F, et al. J. Clin. Pathol. (2006) PMID: 16497872
208. Attri J, et al. BMC Gastroenterol (2005) PMID: 15985168
209. Moore PS, et al. Br. J. Cancer (2001) PMID: 11161385
210. Klump B, et al. Br. J. Cancer (2003) PMID: 12610506
211. Oshima M, et al. Ann. Surg. (2013) PMID: 23470568
212. Geradts J, et al. Mod. Pathol. (2001) PMID: 11706079
213. Chang DT, et al. Cancer (2010) PMID: 20665497
214. Quelle DE, et al. Cell (1995) PMID: 8521522
215. Mutat. Res. (2005) PMID: 15878778
216. Gazzeri S, et al. Oncogene (1998) PMID: 9484839
217. Oncogene (1999) PMID: 10498883
218. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) PMID: 16869746
219. Ozenne P, et al. Int. J. Cancer (2010) PMID: 20549699
220. Ruas M, et al. Oncogene (1999) PMID: 10498896
221. Jones R, et al. Cancer Res. (2007) PMID: 17909018
222. Haferkamp S, et al. Aging Cell (2008) PMID: 18843795
223. Huot TJ, et al. Mol. Cell. Biol. (2002) PMID: 12417717
224. Rizos H, et al. J. Biol. Chem. (2001) PMID: 11518711
225. Gombart AF, et al. Leukemia (1997) PMID: 9324288
226. Yang R, et al. Cancer Res. (1995) PMID: 7780957
227. Parry D, et al. Mol. Cell. Biol. (1996) PMID: 8668202
228. Greenblatt MS, et al. Oncogene (2003) PMID: 12606942
229. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) PMID: 10491434
230. Poi MJ, et al. Mol. Carcinog. (2001) PMID: 11255261
231. Byeon IJ, et al. Mol. Cell (1998) PMID: 9660926
232. Kannengiesser C, et al. Hum. Mutat. (2009) PMID: 19260062
233. Lal G, et al. Genes Chromosomes Cancer (2000) PMID: 10719365
234. Koh J, et al. Nature (1995) PMID: 7777061
235. McKenzie HA, et al. Hum. Mutat. (2010) PMID: 20340136
236. Miller PJ, et al. Hum. Mutat. (2011) PMID: 21462282
237. Kutscher CL, et al. Physiol. Behav. (1977) PMID: 905385
238. Scaini MC, et al. Hum. Mutat. (2014) PMID: 24659262
239. Jenkins NC, et al. J. Invest. Dermatol. (2013) PMID: 23190892
240. Walker GJ, et al. Int. J. Cancer (1999) PMID: 10389768
241. Rutter JL, et al. Oncogene (2003) PMID: 12853981
242. Whelan AJ, et al. N Engl J Med (1995) PMID: 7666917
243. Adv Exp Med Biol (2010) PMID: 20687502
244. Hogg D, et al. J Cutan Med Surg (1998) PMID: 9479083
245. De Unamuno B, et al. Melanoma Res (2018) PMID: 29543703
246. Soura E, et al. J Am Acad Dermatol (2016) PMID: 26892650
247. Huerta C, et al. Acta Derm Venereol (2018) PMID: 29405243
248. Kaufman DK, et al. Neurology (1993) PMID: 8414022
249. Bahuaui M, et al. Cancer Res (1998) PMID: 9622062
250. Chan AK, et al. Clin Neuropathol () PMID: 28699883
251. Hirai H, et al. Cancer Biol. Ther. (2010) PMID: 20107315
252. Bridges KA, et al. Clin. Cancer Res. (2011) PMID: 21799033
253. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) PMID: 21389100
254. Osman AA, et al. Mol. Cancer Ther. (2015) PMID: 25504633
255. Xu L, et al. Mol. Cancer Ther. (2002) PMID: 12489850
256. Xu L, et al. Mol. Med. (2001) PMID: 11713371
257. Camp ER, et al. Cancer Gene Ther. (2013) PMID: 23470564
258. Kim SS, et al. Nanomedicine (2015) PMID: 25240597
259. Pirolo KF, et al. Mol. Ther. (2016) PMID: 27357628
260. Leijen S, et al. J. Clin. Oncol. (2016) PMID: 27601554
261. Moore et al., 2019; ASCO Abstract 5513
262. Leijen S, et al. J. Clin. Oncol. (2016) PMID: 27998224
263. Oza et al., 2015; ASCO Abstract 5506
264. Lee J, et al. Cancer Discov (2019) PMID: 31315834
265. Méndez E, et al. Clin. Cancer Res. (2018) PMID: 29535125
266. Seligmann JF, et al. J Clin Oncol (2021) PMID: 34538072
267. Gourley et al., 2016; ASCO Abstract 5571
268. Park H, et al. ESMO Open (2022) PMID: 36084396
269. Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) PMID: 20018721
270. Scarpa A, et al. Am. J. Pathol. (1993) PMID: 8494051
271. Luo Y, et al. Pathol. Oncol. Res. (2013) PMID: 22782330
272. Iacobuzio-Donahue CA, et al. Clin. Cancer Res. (2012) PMID: 22896692
273. Macgregor-Das AM, et al. J Surg Oncol (2013) PMID: 22806689
274. Ottenhof NA, et al. Cell Oncol (Dordr) (2012) PMID: 22351431
275. Tsiambas E, et al. J BUON () PMID: 20414934
276. Ansari D, et al. Br J Surg (2011) PMID: 21644428
277. Grochola LF, et al. Pancreas (2011) PMID: 21404460
278. Brown CJ, et al. Nat. Rev. Cancer (2009) PMID: 19935675
279. Joerger AC, et al. Annu. Rev. Biochem. (2008) PMID: 18410249
280. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) PMID: 12826609
281. Kamada R, et al. J. Biol. Chem. (2011) PMID: 20978130
282. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) PMID: 28472496
283. Yamada H, et al. Carcinogenesis (2007) PMID: 17690113
284. Bougeard G, et al. J. Clin. Oncol. (2015) PMID: 26014290
285. Sorrell AD, et al. Mol Diagn Ther (2013) PMID: 23355100
286. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) PMID: 11219776
287. Kleihues P, et al. Am. J. Pathol. (1997) PMID: 9006316
288. Gonzalez KD, et al. J. Clin. Oncol. (2009) PMID: 19204208
289. Lalloo F, et al. Lancet (2003) PMID: 12672316
290. Mandelker D, et al. Ann. Oncol. (2019) PMID: 31050713
291. Jaiswal S, et al. N. Engl. J. Med. (2014) PMID: 25426837
292. Genovesi G, et al. N. Engl. J. Med. (2014) PMID: 25426838
293. Xie M, et al. Nat. Med. (2014) PMID: 25326804
294. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) PMID: 28669404
295. Severson EA, et al. Blood (2018) PMID: 29678827
296. Fuster JJ, et al. Circ. Res. (2018) PMID: 29420212
297. Hematology Am Soc Hematol Educ Program (2018) PMID: 30504320
298. Chabon JJ, et al. Nature (2020) PMID: 32269342
299. Razavi P, et al. Nat. Med. (2019) PMID: 31768066
300. Del Conte G, et al. Br. J. Cancer (2014) PMID: 25025963
301. Golan et al., 2021; ASCO Abstract 378
302. Golan et al., 2018; ASCO Abstract 297

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # **ORD-1514793-01**
APPENDIX
References

- | | | |
|--|---|--|
| 303. Maio et al., 2021; AACR Abstract CT178 | 30051098 | 316. de Bono J, et al. Cancer Discov (2017) PMID: 28242752 |
| 304. Konstantinopoulos et al., 2018; ASCO Abstract 106 | 310. Reiss KA, et al. J Clin Oncol (2021) PMID: 33970687 | 317. Lu E, et al. J Natl Compr Canc Netw (2018) PMID: 30099369 |
| 305. Reiss KA, et al. Lancet Oncol (2022) PMID: 35810751 | 311. Binder et al., 2019; AACR Abstract CT234 | 318. De Bono et al., 2020; ASCO Abstract 5566 |
| 306. Mirza et al., 2016; ASCO Abstract 5555 | 312. Turner et al., 2017; ASCO Abstract 1007 | 319. Gruber et al., 2019; ASCO Abstract 3006 |
| 307. Kristeleit et al., 2014; ASCO Abstract 2573 | 313. Litton JK, et al. N. Engl. J. Med. (2018) PMID: 30110579 | 320. Piha-Paul et al., 2017; EORTC-NCI-AACR Abstract A096 |
| 308. Domcheck et al., 2016; ASCO Abstract 4110 | 314. Ettl J, et al. Ann. Oncol. (2018) PMID: 30124753 | |
| 309. Shroff RT, et al. JCO Precis Oncol (2018) PMID: | 315. Meehan et al., 2017; AACR Abstract 4687 | |

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 09 December 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531